Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014)
Coherus Oncology (CHRS) reported Preferred Stock Liabilities of $161.2 million for Q3 2014, up 194.66% sequentially from $54.7 million in Q4 2013.
Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Coherus Oncology (CHRS) has 2 years of Preferred Stock Liabilities data on file, last reported at $161.2 million in Q3 2014.
- For the quarter ending Q3 2014, Preferred Stock Liabilities changed N/A year-over-year to $161.2 million; the trailing twelve-month figure through Sep 2014 stood at $161.2 million (changed N/A YoY), and the FY2013 full-year result was $54.7 million, up 993.9% from the prior year.
- Preferred Stock Liabilities climbed to $161.2 million in Q3 2014, from $54.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $161.2 million in Q3 2014 to a low of $54.7 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 161.16 Mn |
| Dec 31, 2013 | 54.70 Mn |